Name

Tungsten Advisors

Legal name

Tungsten Partners LLC

Website

https://www.tungstenadv.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Marketing channels4 records

Core offering

Tungsten Advisors is a merchant banking firm for healthcare companies that originates and executes bespoke financing, licensing, and M&A solutions. The firm advises life sciences (therapeutics, diagnostics, devices) and healthcare technology (digital health, tech-enabled services, data science) clients on private placements, PIPEs, registered directs, equity lines of credit, inward and outward corporate licensing, acquisitions, divestments, carve-outs, and SPAC mergers. Securities transactions are conducted through Finalis Securities LLC, a registered broker-dealer and FINRA/SIPC member.

Product overview

Tungsten Advisors is a merchant banking firm for healthcare companies that provides a unified platform of three core advisory services: financing solutions (private placements, PIPEs, registered directs, and equity lines), licensing advisory (inward and outward corporate licensing of global and regional rights), and mergers & acquisitions advisory (acquisitions, divestments, carve-outs, and SPAC mergers). The firm specializes in life sciences (therapeutics, diagnostics, devices) and technology (digital health, tech-enabled services, data science) sectors, operating as a single integrated advisory offering rather than discrete product modules.

Differentiator

Problem solved

Functional benefit

Products and services

• Financing Advisory Services Advisory and placement agent services for healthcare companies seeking capital, including Private Placements (PP), Private Investment in Public Equity (PIPE), Registered Direct (RD), Confidentially Marketed Public Offering (CMPO), and Equity Line of Credit (ELOC). Intended for therapeutics, diagnostics, devices, digital health, and tech-enabled services companies needing dilutive or non-dilutive financing.
• Licensing Advisory Services Advisory services for Inward Corporate Licensing (ICL) and Outward Corporate Licensing (OCL) of global and regional rights, targeting pharmaceutical, biotech, and medical technology companies seeking corporate partnerships and licensing transactions.
• Mergers & Acquisitions Advisory M&A advisory services for healthcare and life sciences transactions, including acquisitions, divestments (spin-offs, split-offs, carve-outs, asset sales), SPAC mergers, and fairness opinions.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Ferghana Partners: Boutique healthcare and chemicals advisory firm where co-founder Romy Seth previously worked. Directly comparable as a specialist merchant bank serving therapeutics, life sciences, and specialty chemicals sectors with financing and M&A mandates.
• Solebury Trout: Boutique healthcare equity capital markets and advisory firm where Transaction Advisors Jonathan Fassberg and Brian Korb were Co-CEO and Co-Head of Healthcare. Comparable in serving healthcare and life sciences clients with financing and IR advisory.
• Trout Capital: Healthcare-focused boutique capital markets advisory with deep biotech placement agent expertise. Highly comparable to Tungsten's PIPE, RD, and equity financing offerings for healthcare companies.
• Brean Capital: Healthcare-focused boutique investment bank where VP Jake Foley worked in life sciences and medical devices. Comparable boutique structure serving financing and M&A mandates for healthcare companies.
• Astr Partners: Co-founded by Tungsten Transaction Advisors Jonathan Fassberg and Brian Korb. Healthcare-focused boutique advisory firm comparable in size, scope, and target client base.

Broad incumbents

• Oppenheimer & Co. (Healthcare Investment Banking): Full-service investment bank with a dedicated healthcare team where Brian Korb and Jonathan Fassberg previously held MD and Vice Chairman roles. Competitor for healthcare financing and M&A mandates but broader service mix.
• Jefferies (Healthcare Investment Banking): Global investment bank with a leading healthcare franchise where Managing Director Michael Friedman previously worked. Comparable healthcare sector coverage but with much broader product suite and balance-sheet capacity.
• Robert W. Baird & Co. (Healthcare IB): Mid-market investment bank with healthcare franchise where Michael Friedman held investment banking positions. Competes for healthcare financing and M&A but with broader industry coverage.
• TD Cowen (Healthcare): Healthcare-focused investment banking arm of TD Securities with strong biotech franchise. Comparable healthcare specialty but broader parent platform and balance sheet.
• Lazard (Healthcare M&A): Global advisory firm with significant healthcare and life sciences M&A practice. Competes for larger healthcare M&A mandates with broader sector and product reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tungstenadvisors

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tungsten Advisors